🔬 Coriolis brings expertise in drug formulation, while Rentschler offers experience in bioprocessing.
⚗️ Their collaboration aims to tackle challenges in the biopharmaceutical sector efficiently.
🚀 Clients can access these new services starting this month. Both companies operate in Germany and the U.S.
Introduction:
Rentschler Biopharma, a Contract Development and Manufacturing Organization (CDMO), has partnered with Coriolis Pharma, a Contract Research and Development Organization (CRDO), to deliver comprehensive biopharmaceutical solutions. This collaboration aims to streamline the transition from experimental formulation to commercial manufacturing by integrating their respective areas of expertise in biopharma development.
- The partnership combines Rentschler Biopharma’s bioprocess development and manufacturing experience with Coriolis Pharma’s formulation and analytical capabilities.
- This collaboration promises more efficient and expedited solutions to complex challenges throughout the biopharmaceutical value chain.
- Both companies emphasize the significance of science-driven solutions to enhance project progression for their clients.
- The integrated service offering is set to be available immediately to clients, with operations extending across Germany and the U.S.
- The collaboration is seen as a strategic response to the growing need for comprehensive biopharma solutions in the industry.
Conclusion:
The collaboration between Rentschler Biopharma and Coriolis Pharma represents a significant advancement in the provision of integrated biopharmaceutical services. By leveraging each company’s unique strengths, the partnership anticipates addressing emerging challenges in biopharmaceutical development and manufacturing, thereby potentially improving outcomes for clients in this rapidly evolving field. Such collaborations may set a precedent for future partnerships aimed at optimizing biopharmaceutical processes.
